The correlation between the expression of ubiquitin-conjugating enzyme 2C and prostate cancer prognosis.
Prognosis
Prostate cancer
UBE2C
Ubiquitin
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
11
10
2022
accepted:
27
01
2023
medline:
24
7
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Ubiquitin-conjugating enzyme E2 C (UBE2C) is known to show a causal relationship with cancer development and advancement. The role of UBE2C is to control the mitotic spindle checkpoint. Excess UBE2C has been identified in patients with advanced prostate cancer. The objective of the present study was to examine positive connections between the expression of UBE2C and prognostic factors for prostate cancer. Prostate cancer patients' clinical data were analysed. Tissue microarrays (TMAs) were also performed for human prostate cancer tissues (n = 335) and adjacent non-neoplastic tissues (n = 22). TMA slides were incubated with antibodies against UBE2C. Cores were scored by a pathologist who was blind to cancer results. Of 335 prostate cancer patients, 200 could be assessed for biochemical recurrence, clinical recurrence, and overall survival. Human prostate cancer tissues showed higher expression of UBE2C than adjacent non-neoplastic tissues. High expression level of UBE2C showed a strong positive relationship with a high prostate-specific antigen (PSA), Gleason's score, and pathological stage of prostate cancer. Patients with a higher UBE2C grade demonstrated greater lymphatic engagement of prostate cancer than those with a lower UBE2C grade. The expression of UBE2C has positive correlations with several prognostic factors for prostate cancer. Thus, investigating the expression level of UBE2C staining is a promising tool for predicting prostate cancer prognosis.
Identifiants
pubmed: 36752909
doi: 10.1007/s00432-023-04611-7
pii: 10.1007/s00432-023-04611-7
doi:
Substances chimiques
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6351-6360Subventions
Organisme : Soonchunhyang University
ID : 000
Organisme : National Research Foundation of Korea
ID : 2021R1A2C1004163
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Berlingieri M, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A, Barbareschi M, Barbareschi M, Ferro A, Troncone G, Fusco A (2007) UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene 26(14):2136–2140
doi: 10.1038/sj.onc.1210010
pubmed: 17016443
Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW (2017) Prostate cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(3):245–253
doi: 10.3322/caac.21391
pubmed: 28222223
pmcid: 6375094
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439
doi: 10.1001/jama.294.4.433
pubmed: 16046649
Fujita K, Nonomura N (2019) Role of androgen receptor in prostate cancer: a review. World J Mens Health 37(3):288–295
doi: 10.5534/wjmh.180040
pubmed: 30209899
Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H (2009) Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer 9(1):1–10
doi: 10.1186/1471-2407-9-87
Hao Z, Zhang H, Cowell J (2012) Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol 33(3):723–730
doi: 10.1007/s13277-011-0291-1
pubmed: 22170434
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479
doi: 10.1146/annurev.biochem.67.1.425
pubmed: 9759494
Jin L, Williamson A, Banerjee S, Philipp I, Rape M (2008) Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Mol Cell 133(4):653–665
Joazeiro CA, Weissman AM (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102(5):549–552
doi: 10.1016/S0092-8674(00)00077-5
pubmed: 11007473
Kim JH, Oh E, Han YS, Lee SH, Song YS (2021a) Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in castration-resistant prostate cancer. Prostate Int 9(1):31–41
doi: 10.1016/j.prnil.2020.07.002
pubmed: 33912512
Kim JH, Yang HJ, Lee CH, Jeon YS, Park JJ, Lee KW, Kim JH, Song SJ, Kim YH, Moon AR, Lee JH et al (2021b) The Positive Correlations between the expression of histopathological ubiquitin-conjugating enzyme 2o staining and prostate cancer advancement. Pharmaceuticals (basel) 14(8):778
doi: 10.3390/ph14080778
pubmed: 34451875
Lin Y, Hwang WC, Basavappa R (2002) Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem 277(24):21913–21921
doi: 10.1074/jbc.M109398200
pubmed: 11927573
Lin J, Raoof DA, Wang Z, Lin M-Y, Thomas DG, Greenson JK, Giordano TJ, Orringer MB, Chang AC, Beer DG, Lin L (2006) Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia 8(12):1062–1071
doi: 10.1593/neo.05832
pubmed: 17217624
pmcid: 1783715
Lu J, Wen M, Huang Y, He X, Wang Y, Wu Q, Li Z, Castellanos-Martin A, Abad M, Cruz-Hernandez JJ et al (2013) C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics 8(6):571–583
doi: 10.4161/epi.24626
pubmed: 23770814
pmcid: 3857337
Meyer H-J, Rape M (2011) Processive ubiquitin chain formation by the anaphase-promoting complex. Semin Cell Dev Biol 22:544–550
doi: 10.1016/j.semcdb.2011.03.009
pubmed: 21477659
pmcid: 3201729
Nath S, Banerjee T, Sen D, Das T, Roychoudhury S (2011) Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10. J Biol Chem 286(18):15666–15677
doi: 10.1074/jbc.M110.160671
pubmed: 21454660
pmcid: 3091175
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A (2003) UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 63(14):4167–4173
pubmed: 12874022
Pallante P, Berlingieri M, Troncone G, Kruhoffer M, Orntoft T, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Fusco A (2005) UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer 93(4):464–471
doi: 10.1038/sj.bjc.6602721
pubmed: 16106252
pmcid: 2361574
Reddy S, Rape M, Margansky W, Kirschner M (2007) Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 446(7138):921–925
doi: 10.1038/nature05734
pubmed: 17443186
Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV (1997) Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Prosc Natl Acad Sci USA 94(6):2362–2367
doi: 10.1073/pnas.94.6.2362
Van Ree JH, Jeganathan KB, Malureanu L, Van Deursen JM (2010) Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol 188(1):83–100
doi: 10.1083/jcb.200906147
pubmed: 20065091
pmcid: 2812857
Vasiljevic A, Champier J, Figarella-Branger D, Wierinckx A, Jouvet A, Fèvre-Montange M (2013) Molecular characterization of central neurocytomas: potential markers for tumor typing and progression. Neuropathology 33(2):149–161
doi: 10.1111/j.1440-1789.2012.01338.x
pubmed: 22816789
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245–256
doi: 10.1016/j.cell.2009.04.056
pubmed: 19632176
pmcid: 2726827
Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, Chen Z, Chen H, Clinton SK, Chan KK, Wang Q (2011) CCI-779 inhibits cell-cycle G2–M progression and invasion of castration-resistant prostate cancer via attenuation of ube2c transcription and mRNA stability. Cancer Res 71(14):4866–4876
doi: 10.1158/0008-5472.CAN-10-4576
pubmed: 21593191
pmcid: 3138908
Williamson A, Banerjee S, Zhu X, Philipp I, Iavarone AT, Rape M (2011) Regulation of ubiquitin chain initiation to control the timing of substrate degradation. Mol Cell 42(6):744–757
doi: 10.1016/j.molcel.2011.04.022
pubmed: 21700221
pmcid: 3125540
Wu X, Long X, Ma C, Cheuk YC, Hu M, Hu J, Jiang H (2022) Overexpression of ubiquitin-conjugating enzyme E2C is associated with worsened prognosis in prostate cancer. Int J Mol Sci 23(22):13873
doi: 10.3390/ijms232213873
pubmed: 36430352
pmcid: 9695011
Xie C, Powell C, Yao M, Wu J, Dong Q (2014) Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker. Int J Biochem Cell Biol 47:113–117
doi: 10.1016/j.biocel.2013.11.023
pubmed: 24361302
Ye Y, Rape M (2009) Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 10(11):755–764
doi: 10.1038/nrm2780
pubmed: 19851334
pmcid: 3107738